|
Malignant neoplasm of breast
|
0.360 |
Biomarker
|
disease |
BEFREE |
Our results indicate a role of DLC-1 in BC carcinogenesis.
|
12759748 |
2003 |
|
Malignant neoplasm of breast
|
0.360 |
Biomarker
|
disease |
BEFREE |
The RhoGAP protein DLC-1 functions as a metastasis suppressor in breast cancer cells.
|
16024604 |
2005 |
|
Malignant neoplasm of breast
|
0.360 |
Biomarker
|
disease |
BEFREE |
These findings are consistent with a possible tumour suppressor function of DLEC1 in breast cancer.
|
20530412 |
2010 |
|
Malignant neoplasm of breast
|
0.360 |
PosttranslationalModification
|
disease |
BEFREE |
These data suggest that hypermethylation is responsible for silencing of DLC-1 gene in a limited portion of breast cancers.
|
15201975 |
2004 |
|
Malignant neoplasm of breast
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
The correlation between DLC-1 expression level and tumor progression and metastasis of breast cancer was negative.
|
22799310 |
2012 |
|
Malignant neoplasm of breast
|
0.360 |
Biomarker
|
disease |
BEFREE |
Furthermore, introduction of the DLC-1 cDNA abolished the in vivo tumorigenicity in nude mice, suggesting that the DLC-1 gene plays a role in breast cancer by acting as a bona fide tumor suppressor gene.
|
12545165 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
DLC-1 (deleted in liver cancer-1) is a potential tumor suppressor gene, which is inactive in liver carcinogenesis.
|
18288400 |
2008 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
DLC-1 expression was not found to be associated with tumor differentiation status.
|
26514520 |
2015 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Expression profile of the tumor suppressor genes DLC-1 and DLC-2 in solid tumors.
|
17016643 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Two related Rho GTPase-activating proteins, DLC-1 (deleted in liver cancer 1) and DLC-2, are emerging as bona fide tumor suppressor genes that inhibit cancer cell growth.
|
17297465 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
While the pathogenic relevance of the intronic polymorphism is not known, the low rate of mutation of the DLC-1 gene in HCC implies that genomic deletion and promoter methylation primarily account for the altered expression and tumor suppressive inactivation of the DLC-1 gene.
|
12792785 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
DLC-1 operates as a tumor suppressor gene in human non-small cell lung carcinomas.
|
14661059 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings suggest that DLC-1 may play an important role in lymphoma by acting as a bona fide new tumor suppressor gene.
|
20882354 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
More than a 10-fold increase in mRNA expression was observed for two previously identified tumor suppressor genes (DLC-1 and DCC) and also for RPIB9 and PCDHGA12.
|
17363581 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Deleted in lung and esophageal cancer 1 (DLEC1) is a tumor suppressor gene with reduced transcriptional activity and promoter hypermethylation in various cancers, including colorectal cancer.
|
25640947 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We defined DLEC1 down-expression as a 2-fold decrease in expression of DLEC1 between normal tissues and tumors, and determined its correlation with clinical characteristics.
|
20952247 |
2010 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
To determine whether aberrant methylation is a contributing factor to transcriptional inactivation of DLC-1 (deleted in liver cancer-1), a candidate tumor suppressor gene, we examined its methylation status in twelve hepatocellular carcinoma. breast, colon, and prostate tumor cell lines with low or undetectable expression of DLC-1.
|
12645648 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The tumor suppressor DLEC1 has been shown to promote cell proliferation when AP-2α2 is down-regulated in HCT116 stable clones, suggesting its pro-survival nature.
|
30607648 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
DLC-1 (deleted in liver cancer-1) is a tumor suppressor gene for hepatocellular carcinoma and other cancers.
|
17292327 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Restoration of DLC-1 expression in RCC cells led to Bcl-2 and caspase-3 mediated apoptosis as well as attenuated the ability of the cells to form RCC tumors in athymic nude mice (P<0.05).
|
19380190 |
2009 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Promoter hypermethylation of DLEC1 was also detected in 30 of 42 (71%) NPC primary tumors.
|
17099870 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Absence or low expression of DLC-1, a tumor suppressor gene, in breast cancers has been shown recently.
|
15201975 |
2004 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
DLEC1 methylation was only associated with tumor size.
|
26550574 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
DLC-1 (deleted in liver cancer 1) is a candidate tumor suppressor gene for hepatocellular carcinoma and other cancers.
|
12034501 |
2002 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The nine genes validated in tissues also showed a significantly higher frequency of tumor-specific hypermethylation in NSCLC plasma, as compared with the cancer-free plasmas, and a 5-gene set (APC, RASSF1A, CDH13, KLK10 and DLEC1) achieved a sensitivity of 83.64% and a specificity of 74.0% for cancer diagnosis.
|
21255913 |
2011 |